Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride

Drug Development and Industrial Pharmacy

Volumn 39, Issue 3, 2013, Pages 499-506

  Zhu, Jia Xiao ^a,b   Tang, Dan ^a,b   Feng, Liang ^a   Zheng, Zhao Guang ^a,b   Wang, Ru Shang ^a   Wu, An Guo ^a   Duan, Ting Ting ^a,b   He, Bao ^a   Zhu, Quan ^a,b  

^a MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^b Institute of Consun Co for Chinese Medicine in Kidney Diseases   (China)

Author keywords

Berberine hydrochloride; Bioavailability; in vitro release; Microemulsion; Self microemulsifying drug delivery system

Indexed keywords

BERBERINE; EMULSIFYING AGENT; LINOLEIC ACID ETHYL ESTER; OIL; OLEIC ACID; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORPHOLOGY; NONHUMAN; RAT; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SOLUBILIZATION; TABLET; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BERBERINE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; EMULSIONS; PARTICLE SIZE; RATS; SOLUBILITY;

EID: 84873685615     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.683875     Document Type: Article

References (35)

1. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y et al. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55:2256-2264.
2. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H et al. (2008). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMPactivated protein kinase and improve insulin action. Diabetes, 57:1414-1418.
3. Letasiov S, Jantov S, Cip L, Mkov M. (2006). Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett, 239:254-262.
4. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. (2008). Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res, 68:5370-5379.
5. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY. (2007). Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res, 56:193-201.
6. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 10:1344-1351.
7. Tan W, Li Y, Chen M, Wang Y. (2011). Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine, 6:1773-1777.
8. Asada H, Douen T, Waki M, Adachi S, Fujita T, Yamamoto A et al. (1995). Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci, 84:682-687.
9. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89:429-442.
10. Sakuma S, Hayashi M, Akashi M. (2001). Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev, 47:21-37.
11. Janes KA, Calvo P, Alonso MJ. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 47:83-97.
12. Wang J, Chow D, Heiati H, Shen WC. (2003). Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release, 88:369-380.
13. Dong Z, Hamid KA, Gao Y, Lin Y, Katsumi H, Sakane T et al. (2011). Polyamidoamine dendrimers can improve the pulmonary absorption of insulin and calcitonin in rats. J Pharm Sci, 100:1866-1878.
14. Yu C, Gu P, Zhang W, Qi N, Cai C, He H et al. (2011). Preparation and evaluation of zolmitriptan submicron emulsion for rapid and effective nasal absorption in beagle dogs. Drug Dev Ind Pharm, 37:1509-1516.
15. Ghosh PK, Murthy RS. (2006). Microemulsions: a potential drug delivery system. Curr Drug Deliv, 3:167-180.
16. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Lee YI, Kim DD et al. (2009). Enhanced oral bioavailability of Coenzyme Q10 by selfemulsifying drug delivery systems. Int J Pharm, 374:66-72.
17. Qi X, Wang L, Zhu J. (2011). Water-in-oil-in-water double emulsions: an excellent delivery system for improving the oral bioavailability of pidotimod in rats. J Pharm Sci, 100:2203-2211.
18. Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP. (2009). Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm, 35:603-611.
19. Wu X, Xu J, Huang X, Wen C. (2011). Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm, 37:15-23.
20. Wu W, Wang Y, Que L. (2006). Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm, 63:288-294.
21. Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm, 355:269-276.
22. Constantinides PP. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res, 12:1561-1572.
23. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. (2007). Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm, 66:227-243.
24. Pouton CW. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci, 11 Suppl 2:S93-S98.
25. Humberstone AJ, Charman WN. (1997). Lipid vehicles for the drug delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103-128.
26. Grove M, Mlertz A, Nielsen JL, Pedersen GP. (2006). Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci, 28:233-242.
27. O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405-415.
28. Swenson ES, Mehta SC, Radebaugh GW. (1994). Targeting lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator via a formulation approach. Int J Pharm, 108:85-93.
29. Klous MG, Nuijen B, Van den Brink W, Van Ree JM, Beijnen JH. (2004). Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach. Int J Pharm, 285:65-75.
30. Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Selfemulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 212:233-246.
31. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. (2004). Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull, 27:1993-1999.
32. Venkatesh G, Majid MI, Mansor SM, Nair NK, Croft SL, Navaratnam V. (2010). In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone. Drug Dev Ind Pharm, 36:735-745.
33. Wang Y, Sun J, Zhang T, Liu H, He F, He Z. (2011). Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems. Drug Dev Ind Pharm, 37:1225-1230.
34. Patel AR, Vavia PR. (2007). Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J, 9:E344-E352.
35. Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H et al. (2009). Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm, 371:148-155.